
Beginning with zzso a decade ago, therapy based on targeted zzso of the zzso zzso has greatly improved the prognosis for chronic zzso leukemia zzso zzso The recognition that some patients experience zzso due to zzso point zzso within zzso sparked the development of the second-generation zzso zzso zzso zzso and zzso zzso these drugs target most resistant zzso zzso with the exception of zzso A third wave of advances is now cresting in the form of zzso zzso zzso whose target profile encompasses zzso The leading third-generation clinical candidate for zzso zzso including patients with the zzso zzso is zzso zzso a zzso inhibitor that has entered pivotal phase 2 zzso A second inhibitor with activity against the zzso zzso zzso is in phase 1 clinical zzso We provide an up-to-date synopsis of zzso signaling zzso highlight new findings on mechanisms underlying zzso zzso acquisition and disease zzso discuss the use of zzso and zzso in a zzso capacity, and evaluate zzso zzso and other zzso zzso zzso with activity against zzso in the development zzso 

